ArticleScientific reports2025
The apoptotic and anti-metastatic effects of niosome kaempferol in MCF-7 breast cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Employing Streptomyces enissocaesilis as a sustainable cell factory for green synthesis of gold nanoparticles with multi-target anticancer activity against MCF-7 breast cancer cells.Microbial cell factories · 2026Article
- First evidence for isolation and characterization of Bacopa monnieri (L.) Wettst-derived nanovesicles with anti-neuroblastoma potential.Scientific reports · 2026Article
- Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies.Discover oncology · 2026Review
- Rosa roxburghii Tratt fruit polysaccharides inhibit proliferation and induce apoptosis in human cervical cancer cell line.Translational cancer research · 2026Article
- Puerarin-Loaded Proniosomal Gel: Formulation, Characterization,Gels (Basel, Switzerland) · 2026Article
- Anticancer Activity and Cell Mechanism of a Novel Flavonoid Derivative fromCancer management and research · 2026Article
- Dissecting the mechanistic actions of kaempferol in breast and ovarian cancers: pathway-level insights and translational potential.Frontiers in oncology · 2026Review
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Anticancer Effect of Kaempferol Through Downregulation of CDKs and PD-L1 in Triple-Negative Breast Cancer Cells.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaempferol (KMF) possesses notable anti-tumor bioactivity, which indicates its promising action in the therapy of gynecologic cancers. Here, we examined the therapeutic potential of the naturally occurring flavonoid kaempferol coated on niosome nanoparticles (NPs) and its impact on the breast cancer cell line MCF-7. Niosome NPs containing KMF were prepared by thin-layer hydration. The generated niosome/KMF NPs cytotoxicity on MCF-7 and MCF-10 cell lines were assessed by MTT assay. The physicochemical properties of the niosome/KMF NPs were characterized by SEM, DLS zeta potential, and FTIR. Flow cytometry was used to quantify primary and secondary apoptosis, necrosis and cell cycle arrest. Finally, the expression of apoptosis (Bax and caspase 3) and metastasis genes (ITGA5 and MMP2) was analyzed by Real-time PCR. A Scratch test was performed to investigate the anti-metastatic effect of synthesized nanoparticles. The results showed that the synthesized niosome/KMF NPs have a diameter of 500 nm, a zeta potential of 33.9 mV and a PDI of 0.169. The FTIR spectrum of niosome NPs containing KMF showed distinct peaks in the range of 600-3400 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.